Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,428 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.
Patel S, von Mehren M, Reed DR, Kaiser P, Charlson J, Ryan CW, Rushing D, Livingston M, Singh A, Seth R, Forscher C, D'Amato G, Chawla SP, McCarthy S, Wang G, Parekh T, Knoblauch R, Hensley ML, Maki RG, Demetri GD. Patel S, et al. Among authors: mccarthy s. Cancer. 2019 Aug 1;125(15):2610-2620. doi: 10.1002/cncr.32117. Epub 2019 Jun 7. Cancer. 2019. PMID: 31173362 Free PMC article. Clinical Trial.
Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial.
Hensley ML, Patel SR, von Mehren M, Ganjoo K, Jones RL, Staddon A, Rushing D, Milhem M, Monk B, Wang G, McCarthy S, Knoblauch RE, Parekh TV, Maki RG, Demetri GD. Hensley ML, et al. Among authors: mccarthy s. Gynecol Oncol. 2017 Sep;146(3):531-537. doi: 10.1016/j.ygyno.2017.06.018. Epub 2017 Jun 24. Gynecol Oncol. 2017. PMID: 28651804 Free PMC article. Clinical Trial.
Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.
Jones RL, Demetri GD, Schuetze SM, Milhem M, Elias A, Van Tine BA, Hamm J, McCarthy S, Wang G, Parekh T, Knoblauch R, Hensley ML, Maki RG, Patel S, von Mehren M. Jones RL, et al. Among authors: mccarthy s. Ann Oncol. 2018 Sep 1;29(9):1995-2002. doi: 10.1093/annonc/mdy253. Ann Oncol. 2018. PMID: 30084934 Free PMC article. Clinical Trial.
Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN.
Shen J, Chowdhury S, Agarwal N, Karsh LI, Oudard S, Gartrell BA, Feyerabend S, Saad F, Pieczonka CM, Chi KN, Brookman-May SD, Rooney B, Bhaumik A, McCarthy SA, Bevans KB, Mundle SD, Small EJ, Smith MR, Graff JN. Shen J, et al. Among authors: mccarthy sa. Br J Cancer. 2024 Jan;130(1):73-81. doi: 10.1038/s41416-023-02492-8. Epub 2023 Nov 11. Br J Cancer. 2024. PMID: 37951974 Free PMC article.
Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer.
Mita AC, Papadopoulos K, de Jonge MJ, Schwartz G, Verweij J, Mita MM, Ricart A, Chu QS, Tolcher AW, Wood L, McCarthy S, Hamilton M, Iwata K, Wacker B, Witt K, Rowinsky EK. Mita AC, et al. Among authors: mccarthy s. Br J Cancer. 2011 Sep 27;105(7):938-44. doi: 10.1038/bjc.2011.332. Epub 2011 Aug 30. Br J Cancer. 2011. PMID: 21878940 Free PMC article. Clinical Trial.
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.
Saad F, Efstathiou E, Attard G, Flaig TW, Franke F, Goodman OB Jr, Oudard S, Steuber T, Suzuki H, Wu D, Yeruva K, De Porre P, Brookman-May S, Li S, Li J, Thomas S, Bevans KB, Mundle SD, McCarthy SA, Rathkopf DE; ACIS Investigators. Saad F, et al. Among authors: mccarthy sa. Lancet Oncol. 2021 Nov;22(11):1541-1559. doi: 10.1016/S1470-2045(21)00402-2. Epub 2021 Sep 30. Lancet Oncol. 2021. PMID: 34600602 Free PMC article. Clinical Trial.
Efficacy and safety exposure-response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study.
T'jollyn H, Ackaert O, Chien C, Lopez-Gitlitz A, McCarthy S, Ruixo CP, Karsh L, Chi K, Chowdhury S, Ruixo JP, Agarwal N. T'jollyn H, et al. Among authors: mccarthy s. Cancer Chemother Pharmacol. 2022 May;89(5):629-641. doi: 10.1007/s00280-022-04427-1. Epub 2022 Apr 2. Cancer Chemother Pharmacol. 2022. PMID: 35366072 Clinical Trial.
Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer.
Aggarwal R, Alumkal JJ, Szmulewitz RZ, Higano CS, Bryce AH, Lopez-Gitlitz A, McCarthy SA, Miladinovic B, McQuarrie K, Thomas S, Zhang K, Small EJ. Aggarwal R, et al. Among authors: mccarthy sa. Prostate Cancer. 2022 Sep 28;2022:5454727. doi: 10.1155/2022/5454727. eCollection 2022. Prostate Cancer. 2022. PMID: 36212187 Free PMC article.
Apalutamide for metastatic, castration-sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double-blind, placebo-controlled phase 3 TITAN study.
Uemura H, Arai G, Uemura H, Suzuki H, Iijima K, Nishimura K, Fujii K, Hatayama T, Aoyama J, Deprince K, Lopez-Gitlitz A, McCarthy S, Larsen JS, Li J, Chi KN. Uemura H, et al. Among authors: mccarthy s. Int J Urol. 2021 Mar;28(3):280-287. doi: 10.1111/iju.14447. Epub 2020 Dec 8. Int J Urol. 2021. PMID: 33295007 Clinical Trial.
1,428 results